60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia:Meta-regression of predictors of placebo response by Leucht, Stefan et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.schres.2018.05.009
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Leucht, S., Chaimani, A., Leucht, C., Huhn, M., Mavridis, D., Helfer, B., ... Davis, J. M. (2018). 60years of
placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo
response. Schizophrenia Research, 201, 315-323. https://doi.org/10.1016/j.schres.2018.05.009
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
 1 
60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: 
Meta-regression of predictors of placebo response 
 
Stefan Leucht, MD, Anna Chaimani, PhD, Claudia Leucht, MD, Maximilian Huhn, MD, Dimitris 
Mavridis, PhD, Bartosz Helfer, MSc, Myrto Samara, MD, Andrea Cipriani, MD, PhD, John R Geddes, 
MD, Georgia Salanti, PhD, John M. Davis, MD 
 
Word count body of the text: 2947 words, 2 Tables, 1 Figure, 1 Supplementary File 
 
Corresponding author: 
Prof. Stefan Leucht, MD 
Department of Psychiatry and Psychotherapy, Technische Universität München 
Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany 
Tel: +49-89-4140-4249, Fax: +49-89-4140-4888, e-mail: Stefan.Leucht@tum.de 
 
Prof. Andrea Cipriani, MD, PhD, (andrea.cipriani@psych.ox.ac.uk) and Prof. John Geddes, MD, 
(john.geddes@psych.ox.ac.uk), Department of Psychiatry, University of Oxford, Warneford Hospital, 
Oxford OX3 7JX, UK 
Dr. Claudia Leucht, MD, (Claudia.Leucht@tum.de), Dr. Maximilian Huhn, MD, 
(Maximilian.Huhn@tum.de), Bartosz Helfer, MSci, (bartosz.helfer@gmail.com), Dr. Myrto Samara 
(samaramyrto@gmail.com), MD have the same address as Stefan Leucht. 
Dr. Anna Chaimani, PhD, (anna.chaimani@parisdescartes.fr): Paris Descartes University; INSERM, 
UMR1153 Epidemiology and Statistics, Sorbonne Paris Cité Research Center (CRESS), 
METHODS Team; Cochrane France, Paris, France  
*Manuscript
Click here to view linked References
 2 
Dr. Dimitris Mavridis, PhD, (dimi.mavridis@googlemail.com): Department of Hygiene and 
Epidemiology, University of Ioannina School of Medicine, University Campus Ioannina 45110, Ioannina, 
Greece 
Prof. Georgia Salanti, PhD  (georgia.salanti@ispm.unibe.ch): Institute of Social and Preventive Medicine 
(ISPM). University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland 
Prof. John M. Davis, MD (davisjm@uic.edu): Psychiatric Institute, University of Illinois at Chicago (mc 
912), 1601 W. 
 Taylor St., Chicago, IL 60612, and Maryland Psychiatric Research Center, Baltimore, MD, USA  
 
  
 3 
ABSTRACT 
Objective: A recent meta-regression had shown that the degree of placebo response, which has increased 
over the decades, is the major predictor of drug-placebo differences in antipsychotic drug trials in acutely 
ill patients with schizophrenia. Drug response, however, had remained stable. In the current meta-
regression we explored the factors that are associated with placebo-response.  
Method: We searched multiple electronic databases, ClinicalTrials.gov and the FDA website for 
randomized, placebo-controlled, antipsychotic drug trials in patients with acute exacerbations of 
schizophrenia. The outcome was the degree of placebo response measured by the BPRS or PANSS change 
from baseline to endpoint. 26 patient-, design-, and drug-related potential predictors of placebo response 
were analyzed by univariable and multivariable meta-regressions.  
Results: 167 double-blind randomized controlled trials with 28102 participants were included. The mean 
PANSS change from baseline was 6.25 (95% CI 4.64,7.85). More recent publication year, larger study 
sample size, more study sites, use of the PANSS rather than the BPRS scale to measure response, shorter 
wash-out phases, shorter study duration, lower mean age and shorter duration of illness were associated 
with larger placebo response in univariable analyses. In a multivariable analysis only the number of study 
participants and mean participant age had an impact on placebo response.  
Conclusions: The degree of placebo response is moderated by a number of design and patient-related 
factors. These explanatory variables of placebo response are only in part identical with those that 
moderated drug-placebo differences. 
 
Key Words: placebo response, antipsychotics, meta-regression, clinical trials, predictors 
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1. INTRODUCTION 
 
The efficacy differences between antipsychotic drugs and placebo for acute schizophrenia have decreased 
over the decades (Leucht et al., 2017), explaining in part why in recent years there have been a number of 
failed trials where even standard drugs such as haloperidol did not outperform placebo (049, 2010). This 
decrease in the effect sizes poses a problem for the interpretation of how efficacious antipsychotics really 
are in practice, and the currently small effect sizes in registrational studies as well as other problems such 
as high dropout rates (Rabinowitz et al., 2009) pose a major problem for antipsychotic drug development.  
 
A recent meta-regression analysis showed that the degree of placebo response, which has increased over 
the decades, is the major factor explaining the magnitude of drug-placebo differences (Leucht et al., 
2017). Together with industry-sponsorship, it was the only statistically significant predictor of efficacy 
effect sizes in a multivariable meta-regression. Moreover, when industry-sponsorship, which is probably a 
composite of various factors (e.g. large sample size, multiple centers and countries, recruitment in 
professional centers), was removed from a sensitivity analysis, the degree of placebo-response remained 
the only significant predictor, demonstrating its importance. In contrast, the response in the drug arms of 
these trials had remained stable over the decades. Therefore, which factors explain placebo-response was 
the major remaining question after our previous analysis of drug-placebo differences (Leucht et al., 2017). 
Previous publications have addressed this issue, as well, but they were all based on approximately 2 times 
smaller datasets (Agid et al., 2013; Mallinckrodt et al., 2010; Rutherford et al., 2014). When so many 
more trials are available, the results can easily change, making a new analysis important.  
 
We, therefore, conducted a systematic review and meta-regression analysis of predictors of placebo 
response. As the aim was to understand which factors explained placebo response in the previous report, 
we used the same trials compiled in our recently published database of placebo-controlled antipsychotic 
drug trials in acute schizophrenia, and analysed the same comprehensive list of potential predictors.    
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2. MATERIAL AND METHODS 
We followed the PRISMA guidelines (Liberati et al., 2009) (see checklist in the data supplement S1) and 
initially published a protocol in PROSPERO which also covered the analysis of placebo response 
(CRD42013003342, see data supplement S2). The following methods section corresponds to our previous 
publication with the only major difference that the independent variable was degree of placebo response 
rather than drug-placebo differences.  
 
2.1 Inclusion/exclusion criteria 
2.1.1 Participants 
Adults with acute exacerbations of schizophrenia or related disorders (following the Cochrane 
Schizophrenia Group) were included. We accepted all diagnostic criteria and we also included 
schizoaffective, schizophreniform, or delusional disorder, because these do not require generally different 
treatment (Carpenter and Buchanan, 1994). We excluded relapse prevention studies in stable patients 
receiving maintenance medication (Leucht et al., 2012b), studies in patients with predominant negative 
symptoms, and studies in patients with major concomitant somatic or psychiatric illness.  
2.1.2 Interventions 
We included all antipsychotics licensed in at least one country, except clozapine, a more efficacious drug 
(Leucht et al., 2013a), so that pooling with the other compounds would not have been appropriate (only 
one clozapine arm with nine patients had to be excluded on this basis (Honigfeld, 1984) making the 
impact of this decision negligible). We excluded intramuscular formulations, because these are used 
primarily as sources either for emergency use (short-acting i.m. drugs) or for relapse prevention (long-
acting depot drugs). Only the placebo arms of the included studies were used for the current analysis. 
Types of studies 
Published and unpublished, double-blind, placebo-controlled randomized controlled trials of at least 3 
weeks duration (McMahon et al., 2008) were included. Studies with a high risk in sequence generation or 
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allocation concealment were excluded (Higgins and Green, 2011). We a priori excluded Chinese studies 
due to quality concerns (Woodhead, 2016; Wu et al., 2006). Risk of bias was independently assessed by at 
least two of the following reviewers (CL, SL, MH, BH) with the Cochrane Collaboration’s risk-of-bias 
tool (Higgins and Green, 2011).  
 
2.2 Search strategy 
We searched the Cochrane-Schizophrenia-Group-Controlled-Trials-Register (compiled by regular 
systematic searches of more than 15 databases, clinical trial registers, the FDA website, hand searches and 
conference proceedings (Adams et al., 2011), without language restrictions, available to us until version 
August 2009) with the term “placebo;” and we searched MEDLINE, EMBASE, PsychInfo, Cochrane 
CENTRAL and ClinicalTrials.gov (last search October 2016, search terms are presented in the online 
supplement S3), supplemented by screening previous reviews (Adams et al., 2007; Agid et al., 2013; 
Fenton et al., 2007; Hartung et al., 2005; Joy et al., 2007; Klein and Davis, 1969; Leucht et al., 2009; 
Leucht et al., 2013a; Matar and Almerie, 2007; Omori and Wang, 2009; Shen et al., 2012).  
 
2.3 Outcomes 
The outcome was the mean change from baseline to endpoint of the Positive and Negative Syndrome 
Scale (PANSS, (Kay and Fiszbein, 1987)) total score. If the PANSS was not available we used the change 
from baseline to endpoint of the Brief Psychiatric Rating Scale (BPRS, (Overall and Gorham, 1962)) and 
converted it to the PANSS using a validated method (Leucht et al., 2013b). For this analysis we had 
applied the equi-percentile linking method to identify corresponding scores of simultaneous BPRS and 
PANSS ratings in 3767 patients from six antipsychotic drug trials (Leucht et al., 2013b). Higher PANSS 
change scores means more improvement in the drug group. 
 
2.4 Study selection and data extraction 
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At least two reviewers among MH, MT, MS and SL independently selected potentially relevant 
publications from the abstracts found by our search and decided to include studies, and at least two 
reviewers among CL, MH, BH, MS, MR, SB, MK, PR, TA, NP and SL (see acknowledgement) extracted 
data in duplicate in Excel sheets. Disagreement was resolved by discussion. Missing data were requested 
from authors or the sponsoring pharmaceutical companies for all studies published in the last 30 years. We 
preferably extracted intention-to-treat data and we preferred mixed-effect-model-of-repeated-
measurements (MMRM) models over last-observation-carried-forward (LOCF). Missing standard 
deviations were estimated from test statistics or by using the mean standard deviation of the remaining 
studies (Furukawa et al., 2006).  
 
2.5 Statistical analysis 
We conducted meta-regressions in a frequentist framework with placebo response as the dependent 
variable. Placebo response was a continuous variable defined as the difference in PANSS/BPRS scale 
before and after treatment. Predictors of drug-placebo differences could also be predictors of placebo-
response we considered as independent variables all study and patient characteristics investigated in our 
previous article. Only the drug-related explanatory variables (e.g. antipsychotic drug class, mean dose, 
etc.) were not analysed, because they are not relevant for the placebo groups. The initial choice of 
predictors has been based on previous evidence (Agid et al., 2013; Furukawa et al., 2015; Mallinckrodt et 
al., 2010; Rabinowitz et al., 2014; Rutherford et al., 2014) which suggested that these explanatory 
variables might be relevant. We categorized the explanatory variables into patient-, and study design-
related factors, although there were expected overlaps. We first ran univariable meta-regressions exploring 
separately the effect of each potential explanatory variable. For the multivariable meta-regression model 
we followed a formal variable selection procedure using the backward stepwise algorithm with removal 
criterion p=0.15. We monitored how much heterogeneity in placebo response each predictor explains by 
comparing the heterogeneity of each meta-regression model with the heterogeneity of the model without 
any covariates.  
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2.5.1 Patient-related factors 
The patient-related factors were: chronicity (Agid et al., 2013) measured by the patients’ mean age, 
duration of illness, duration of the current episode and first episode status (Agid et al., 2013; Rabinowitz 
et al., 2014); percentage men (Rabinowitz et al., 2014); US American populations versus not/mixed 
countries (Mattila et al., 2014); severity at baseline (PANSS total score (Furukawa et al., 2014)), in- 
versus outpatient (Agid et al., 2013); and operationalized criteria (e.g. ICD-10 or DSM-III to IV-R) versus 
unspecific ‘clinical diagnoses.’  
2.5.2 Study design-related factors 
We analyzed the impact of risk of bias (appropriate versus unclear randomization (Schulz et al., 1995) and 
allocation concealment methods (Wood et al., 2008), blinding (Wood et al., 2008), and missing outcome 
data (Higgins and Green, 2011; Porta et al., 2007); study duration (Agid et al., 2013); duration of wash-out 
(Agid et al., 2013); requirement of a scale-derived minimum of symptoms at baseline (Furukawa et al., 
2014); PANSS versus BPRS as a scale; sample size (Egger et al., 1997); number of sites (Agid et al., 
2013); percentage of academic sites (Agid et al., 2013); number of medications and arms (Agid et al., 
2013); fixed or flexible dosing (Agid et al., 2013); percentage of participants randomized to placebo 
(Mallinckrodt et al., 2010); and drug company sponsorship of at least one study arm (medication donation 
alone was not considered company sponsorship (Heres et al., 2006)).  
All analyses were performed using Stata 14.2, p<0.05 was considered statistically significant. 
 
3. RESULTS 
3.1 Description of included studies  
The PRISMA (Liberati et al., 2009) flow diagram is presented in the online supplement Figure S1 and a 
description of the included studies in supplement Table S4. Overall, 167 studies published with 28102 
participants met the inclusion criteria, of which 99 studies with 22520 participants (7623 [34%] allocated 
to the placebo group), which were published from 1969 to 2016 provided data on placebo response. In the 
studies with data, the patients’ mean duration of illness was 14.1 (SD 3.6) years, the mean age 38.7 (SD 
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4.7) years and the median duration of studies with useable outcomes was 6 weeks (range 3-26 weeks, for 
the outcome of interest all but one study (26 weeks) lasted ≤12 weeks). There were no studies exclusively 
examining first-episode patients or treatment-resistant patients. Risk of bias is presented in the online 
supplement S5. We only included randomised, double-blind trials, but the reports often did not indicate 
full details about sequence generation, or allocation concealment. Descriptions of methods and success of 
blinding were frequently insufficient, as well. The data confirmed the high dropout rates in current 
schizophrenia studies (mean in the placebo groups 52.0%, SD 25.2). Older studies were poorly reported, 
making it often impossible to extract data (33% of the studies had a high risk of selective reporting). 
Finally, 64 studies (65%) were sponsored by the manufacturers of one antipsychotic included, 28 (28%) 
were not primarily industry sponsored and in 7 (7%) studies the sponsor was unclear. 
 
3.2 Explanatory variables of placebo-response – univariable analysis 
The mean placebo response in PANSS units was 6.25 (95% CI 4.64,7.85; 99 studies (N) with 7623 
participants (n)). This placebo response has increased over the years. The coefficient of 2.74 in Table 1 
indicates that a study published 10 years later than another one had, on average, a 2.74 PANSS units 
higher placebo response. In terms of study design related factors, larger sample size (total number of 
participants and sites), use of PANSS rather than the BPRS, shorter wash-out phases and shorter study 
duration were associated with more placebo response. Concerning patient related factors, after excluding 
an outlier study, the only one restricted to elderly patients with schizophrenia (their mean age was 
approximately 25 years higher than that of the next oldest population (Tzimos et al., 2008)), lower 
participant mean age and lower mean duration of illness were associated with higher placebo-response. 
Moreover, studies conducted exclusively in the US had lower placebo-response than the rest of the studies 
(Table 1).  
 
3.3 Explanatory variables of placebo response – multivariable analysis 
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As some significant predictors are related by nature, we made the following choices for the multivariable 
model: a) We chose publication year to also represent the choice between PANSS versus BPRS to 
measure response, because the PANSS was only introduced in 1987 so that it could not be used previously 
b) we chose sample size as representative for the number of sites, because sample size explained more 
heterogeneity in the univariable analyses. c) we chose mean participant age rather than mean duration ill 
as a measure of chronicity, because more studies reported this outcome and because age explained more of 
the heterogeneity in univariable analyses. Then using backward stepwise algorithm for variable selection, 
total number of participants, age and country were included in the model with the latter not being 
statistically significant (Table 2a). Further, excluding country from the meta-regression model did not 
materially change the results (Table 2b). Finally, as it can be argued that increasing the number of sites 
leads to more variability than increasing the number of patients, we used number of sites rather than 
participants in a post-hoc sensitivity analysis. The results were virtually identical (Table 2c). 
 
4. DISCUSSION 
This meta-regression analysis fills a remaining gap of our previous analysis of predictors of drug-placebo 
differences in antipsychotic drug trials (Leucht et al., 2017). In the previous analysis, placebo-response 
was the single strongest predictor of effect sizes. The average placebo response of 6.25 (95% CI 
4.64,7.85) was almost one third of the average response in the drug arms 17.45 (95% CI 15.89,19.01) 
which had remained stable over the decades (Leucht et al., 2017). Thus, it was important to determine the 
predictors of placebo-response. Our meta-analysis of predictors of placebo response includes two times 
more studies than all previous ones, and we added several potential explanatory variables that had not 
been addressed in previous analyses of this kind.   
 
In univariable analyses publication year, number of participants and sites, shorter wash-out phases, shorter 
study duration, use of the PANSS instead of the BPRS, studies conducted outside the US and less 
chronicity in terms of lower mean age and duration of illness were associated with more placebo response. 
 11 
Among these, publication year, the number of sites, study duration and the measures of chronicity were 
also significant in the next largest analysis of predictors of placebo-response by (Agid et al., 2013). 
Moreover, in both analyses measures of study quality, the number of arms, the percentage of patients 
randomised to placebo, and the percentage of men were not significantly associated with placebo 
response. Given the two times higher number of studies available for our analysis speaks for the 
robustness of the findings about these explanatory variables. It is also important to note that industry-
sponsorship, which was a strong predictor in our analysis of drug-placebo differences (Leucht et al., 2017) 
and in (Agid et al., 2013), was not significant in the current analysis.  Industry sponsorship is probably a 
composite of various factors (e.g. large sample size, multiple centers and countries, recruitment in 
professional centers). As there were many companies involved, an analysis of whether individual 
companies were associated with more placebo-response would have been underpowered. Rutherford et al., 
2014 reported a more complex analysis in this context in which not only placebo-controlled trials but also 
trials that compared antipsychotic drugs with each other were included. Although this difference in 
approaches makes comparison difficult, there were important similarities e.g. that in their analysis placebo 
response had also clearly increased over the years and that sample size and trial duration affected this 
result.   
 
Among the factors that were statistically significant in our results, it is now well established that placebo-
response has increased over the years. The average placebo response was 6.25, so that a study conducted 
in 1970 would have had a worsening in the placebo group of 3 PANSS points, while a study published in 
2015 would have an average placebo response of 10 PANSS points. In our previous report we identified 
multiple design and patient-related factors which have changed over the decades (Leucht et al., 2017). In 
the current report we identified several ones that were also predictors of placebo response. The finding 
that longer wash-out phases were associated with less placebo response may reflect that only once patients 
have been fully washed out from previous treatments they will not respond to placebo. Similarly, a long 
enough trial duration may be needed for patients to show deterioration rather than improvement under 
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placebo. Studies using the PANSS had on average higher placebo response than those using the BPRS. It 
could be that the PANSS is a more sensitive scale than the BPRS, but as the PANSS was introduced only 
in 1987 (Kay and Fiszbein, 1987), this finding was confounded by publication year. The result in our 
analysis that studies conducted entirely in the US were associated with less placebo-response than other 
studies was as surprising as a previous smaller individual-patient data meta-analysis of 21 studies 
including 5233 patients that found drug-placebo differences were smaller in US American studies (Mattila 
et al., 2014). As the degree of placebo response was not examined in this previous meta-analysis, we 
cannot explain the discrepancy, but in our larger meta-analysis of aggregate data, study region was not a 
significant explanatory variable of drug-placebo differences (Leucht et al., 2017).  
 
However, the only factors that were significant in the multivariable model were participant age and the 
number of participants. Increasing participant age was associated with less placebo response. We 
speculate that the symptoms of very chronic patients are quite stable so that they will not change much if 
patients receive a placebo. The other significant factor, sample size (and the related factor number of sites 
which was also a significant factor in (Agid et al., 2013)), is a particularly important variable, because it is 
well-known from other medical fields that small trials lead to larger effect sizes than larger trials 
(Dechartres et al., 2013; Egger et al., 1997). We chose the number of participants rather than the number 
of sites in the multivariable model, because it explained more heterogeneity, but arguably more sites may 
increase variability even more. At the end, we feel that both factors may lead to more variability which 
would reduce drug-placebo differences (effect size = mean group A – mean group B / standard deviation). 
In our previous paper about drug-placebo differences we speculated about a vicious circle of increasing 
sample sizes (and sites), resulting higher variability, smaller effect sizes and which in the next sample size 
estimation would again mean a higher sample size and more sites (Leucht et al., 2017). The current 
analysis confirms that extremely high sample sizes should be avoided in placebo-controlled, antipsychotic 
drug trials.  
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In the comparison with our previous analysis of antipsychotic drugs versus placebo differences, it is 
noteworthy that the explanatory variables which were significant in the current analysis of placebo 
response were not identical with the significant predictors of drug-placebo differences of our previous 
report (Leucht et al., 2017). Concretely, mean patient age and duration of illness, the duration of the wash-
out phase, study duration and country were only significant in the current analysis, while the use of a 
minimum baseline as an entry criterion, industry sponsorship and the number of medications used, were 
only significant explanatory variables of drug-placebo differences (Leucht et al., 2017). This finding is 
important, because it shows that decreasing drug-placebo differences and increasing placebo-response 
over the years are, at least to some extent, different issues which cannot be explained by exactly the same 
phenomena. 
 
Our analysis has limitations. In our previous report we reported that there were small trial 
effects/publication bias in the sense that smaller trials had higher effect sizes than larger ones, and that 
there may be unpublished smaller trials with smaller effect sizes. Accounting for these effects statistically 
reduced the effect size from 0.47 to 0.38 (Leucht et al., 2017). The negative association between sample 
size and placebo response in the current report adds to the interpretation of this finding in that smaller 
trials had less placebo response. Moreover, if all trials had been identified, different predictors could have 
resulted. Second, we excluded relapse prevention studies in stable patients receiving maintenance 
medication, studies in patients with predominant negative symptoms, and studies in patients with major 
concomitant somatic or psychiatric illness. Other factors may be relevant for placebo response in these 
populations. (Fraguas et al., 2018) recently reported that more study sites, more study arms and industry 
sponsorship were significant explanatory variables of placebo response in patients with predominant 
negative symptoms. Thus, there was partial overlap. Third, we have intentionally not updated our search 
since the publication of our previous paper (Leucht et al., 2017). We decided not to update the search, 
because we wanted to understand what predicted placebo response in the studies of our previous analysis 
of drug-placebo differences. If we had updated the search, it would have been unclear whether differences 
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in the predictors identified in both reports were due only to the difference in included studies. 
Nevertheless, our analysis revealed that already four years after the publication of the second-largest 
analysis of predictors of placebo response (Agid et al., 2013), the number of studies had almost doubled. 
Fourth, the variable selection for the final multivariable model was based on the backward stepwise 
algorithm which a) is subject to multicollinearity and b) sometimes leads to over-simplified models by 
erroneously dropping variables with important contribution to model fit. It is therefore important to not 
only focus on the multivariable model, but to consider the results of the univariable model, as well. 
Finally, our multivariable only explained 12% of the heterogeneity. This suggests that there may be 
further undetected and probably unmeasured predictors of placebo response. For example, monitoring, 
which has been made mandatory only relatively recently, may be more difficult to conduct if there are 
many participants. Or there is a speculation about “professional patients/symptomatic volunteers” (Leucht 
et al., 2012a) who participate in trials, e.g. to benefit from small travel fees. Such participants may report 
that they have improved to please their doctors, although they received a placebo. But how many such 
“professional patients” there are is unknown and not recorded. As more trials get published in the future, 
further analyses will be necessary to determine if the current trend of increasing placebo-response and 
decreasing effect sizes could stop. Addressing some of the predictors of placebo-response in our report in 
the methods of future clinical trials could be useful in this regard. 
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Table 1: Univariable meta-regressions 
 
Explanatory variable Coeffi
cient 
95%CI p-value Coefficient 
corresponds to* 
Mean 
value/refer
ence 
category of 
explanator
y variable 
Weighte
d mean 
of 
placebo 
respons
e at the 
mean 
value/re
ference 
categor
y of 
explana
tory 
variable 
95%CI N, n Hete
roge
neity 
SD 
of 
place
bo 
resp
onse 
% 
hetero
geneit
y 
explai
ned 
No covariates - - - -  6.25 4.64,7.8
5 
99,76
23 
8.02 - 
Study design related factors           
Publication yeara 2.74a 1.60, 3.88 <0.001 10-year increase 2001 6.24 4.80,7.7
0 
99,76
23 
7.26 9.5% 
Number of total participantsa 0.16a 0.07, 0.24 <0.001 10 patients more 236 6.24 4.74,7.7
5 
99,76
23 
7.55  5.9% 
Number of sitesa 1.13a 0.45,1.81 0.001 10-site increase 30 6.02 4.39,7.6
6 
90,67
36 
7.80 2.7% 
Minimum duration of the 
wash-out phasea 
-1.41a -2.33, -0.49 0.003 10-day increase 8 5.06 3.39,6.7
3 
84,61
79 
7.70 4.0% 
Study durationa -8.80 -13.97, -
3.63 
0.001 10-week increase 6 weeks 6.58 5.11,8.0
5 
94,75
58 
7.17 10.6% 
Scale (PANNS or BPRS)a 5.96a 2.66,9.26 0.001 BPRS PANSS 2.19 -
0.55,4.9
4 
98,75
96 
7.57 5.6% 
Number of medications -2.19 -5.64,1.25 0.209 More than one 
drugs  
2 drugs 7.75 4.90,10.
61 
99,76
23 
8.00 0.2% 
Baseline severity entry 
minimum score 
-1.17 -5.57,3.23 0.597 With Min. entry 
score 
without 
entry score 
7.91 3.85,11.
98 
75,61
56 
6.76 15.7% 
Industry sponsored drug or not 1.88 -1.49,5.24 0.271 Sponsored non- 5.11 2.30,7.9 92,75 7.48 6.7% 
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sponsored 2 08 
Percentage of academic sites 0.65 -1.35,0.065 0.071 10% increase 56% 4.63 2.15,7.1
2 
53,30
19 
9.01 0% 
Number of arms 2.21 -3.12,7.54 0.412 More than two 
arms 
2 arms 4.26 -
0.79,9.3
1 
99,76
23 
8.04 0% 
Percentage randomized to 
placebo 
-0.99 -3.06,1.08 0.345 10% increase 28.0% 6.25 4.64,7.8
5 
99,76
23 
8.03 0% 
Fixed versus flexible dosing -0.82, -4.52,2.89 0.663 Flexible dose Fixed dose 6.45 4.59,8.3
1 
99,76
23 
8.06 0% 
Randomization -0.13 -3.36,3.09 0.934 Unclear risk low risk 6.32 3.96,8.6
8 
99,76
23 
8.06 0% 
Allocation concealment -1.11 -4.57,2.36 0.528 Unclear risk low risk 7.00 4.14,9.8
7 
99,76
23 
8.05 0% 
Blinding  1.47 -1.75,4.68 0.367 Unclear or high 
risk 
low risk 5.56 3.37,7.7
5 
99,76
23 
8.03 0% 
Risk of bias due to missing 
outcome data  
-2.70 -6.27,0.88 0.138 Unclear or high 
risk 
low risk 6.98 5.12,8.8
5 
99,76
23 
7.97 0.6% 
Patient related factors           
Average agea,c  -4.72a -9.31, -0.13 0.044 10-year increase 38 6.27 4.69,7.8
4 
98,74
45 
7.73 3.6% 
Duration illa,c -9.92a -18.16, -
1.68 
0.149 10-year increase 14 6.27 4.00,8.5
4 
56,46
83 
8.47  
Country a 3.64a 0.48,6.81 0.024 Non-USA or 
mixed study 
USA 4.18 1.80,6.5
6 
99,76
23 
7.85 2.1% 
Baseline severity measured by 
PANSSb 
2.52 -0.59, 5.63 0.111 10-unit PANSS 
increase 
94.6 6.99 5.40,8.5
8 
99,76
23 
7.37 8.1% 
Operationalized criteria or 
not a 
-6.18 -10.97,-1.39 0.012 No 
operationalized 
criteria 
Op.criteria 6.94 5.27,8.6
2 85,70
64 
7.82 2.5% 
Percentage of men 0.20 -0.67,1.07 0.649 10% increase 67.3% 6.50 4.85,8.1
5 
87,70
47 
7.75 3.4% 
aStatistically significant explanatory variables, N = number of studies, n= number of patients, PANSS = Positive and Negative Syndrome Scale, BPRS = Brief 
Psychiatric Rating Scale. bWhen baseline severity was measured by the Clinical Global Impression the result was also not significant (B=4.21 (-2.29, 10.71), B 
corresponds to 1 CGI unit increase. cThese analyses were performed after the exclusion of an outlier study (Tzimos et al., 2008). It was the only study which was 
restricted to elderly patients with schizophrenia. The mean patient age was approximately 25 years higher than that of the next oldest study population. 
Coefficient = coefficient of the meta-regression. 95% CI = 95% confidence interval. SD = standard deviation. 
“Coefficient corresponds to” = for example publication year: a 10-year increase in publication year on the average increases the placebo response by 2.74 PANSS 
units.  
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#Not enough data were available for the variable number of patients with a first episode and there were too few data for ‘duration of the current episode.’ The vast 
majority of studies included only inpatients. Therefore these parameters could not be analyzed in a meaningful way. 
* Coefficient corresponds to a particular increase in the explanatory variable (for continuous characteristics) or to the non-reference category for binary 
characteristics. 
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Table 2a: Multivariable meta-regression model resulted from backward stepwise algorithm 
 
Explanatory 
variable 
Coefficient  95% CrI 
p-value Coefficient 
corresponds 
to 
Interpretation 
Total 
participantsa 
0.15 0.07, 0.24 
0.001 
10 
participants 
more 
For every 10-
participants increase 
in the sample size the 
average placebo 
response increases by 
0.15 PANSS/BPRS 
units  
Average agea -6.23 -10.46, -2.00 
0.004 
10 years 
increase 
For every 10 years 
increase in the 
average participant’s 
age, the average 
placebo response 
decreases by 6.23 
PANSS/BPRS units  
Country 2.57 -0.52, 5.67 
0.102 
 
Non-USA or 
mixed study 
(vs USA) 
For non-USA or 
mixed studies in 
comparison with 
USA studies, the 
average placebo 
response is larger by 
2.57 PANSS/BPRS 
units  
Summary of the model: 95 studies with 22300 participants, heterogeneity standard deviation 7.02, 
the model explained 12% of the heterogeneity 
aStatistically significant explanatory variables.  
 
Table 2b: Multivariable meta-regression model with age and total participants as predictors 
 
Explanatory 
variable 
Coefficient  95% CrI 
p-value Coefficient 
corresponds 
to 
Interpretation 
Total 
participants 
0.18 0.09, 0.26 
<0.001 
10 
participants 
more 
For every 10- 
participants increase 
in the sample size the 
average placebo 
response increases by  
0.18 PANSS/BPRS 
units  
Average agea -5.94 -10.20, -1.69 
0.007 
10 years 
increase 
For every 10 years 
increase in the  
average participant’s 
 22 
age, the average 
placebo response 
decreases by 5.94 
PANSS/BPRS  
Summary of the model: 95 studies with 22300 participants, heterogeneity standard deviation 7.09, 
the model explained 12% of the heterogeneity 
aStatistically significant explanatory variables.  
 
 
Table 2c: Multivariable meta-regression model with age and number of sites as predictors 
 
Explanatory 
variable 
Coefficient  95% CrI 
p-value Coefficient 
corresponds 
to 
Interpretation 
Number of sites 1.38 0.71, 2.04 
<0.001 
10 sites more 
For every 10- sites 
increase the average 
placebo response 
increases by  1.38 
PANSS/BPRS units 
Average agea -6.63 -11.13, -2.14 
0.004 
10 years 
increase 
For every 10 years 
increase in the  
average participant’s 
age, the average 
placebo response 
decreases by 6.63 
PANSS/BPRS 
Summary of the model: 86 studies with 20500 participants, heterogeneity standard deviation 7.27, 
the model explained 9% of the heterogeneity 
aStatistically significant explanatory variables.  
 
 
Legends of Figures 
 
Figure panel 1: Explanatory variables of placebo-response – univariable meta-regressions 
The figures in this panel correspond to the following explanatory variables: a) Publication year, b) 
Number of participants, c) Number of sites, d) Mean age in years, e) Mean duration of illness in years, f) 
Study duration in weeks, g) Minimum duration of the wash-out phase in days, h) Scale used – PANSS or 
BPRS, i) Study region, j) Mean PANSS total score at baseline, k) Percentage of men, l) Percentage of 
academic sites, m) Percentage of patients randomised to placebo, n) minimum scale-derived severity 
threshold as inclusion criterion, o) number of drugs, p) number of arms, q) Operationalised critera or not, 
r) industry-sponsored study or not, s) risk of bias concerning randomization method, t) risk of bias 
 23 
concerning allocation concealment, u) risk of bias concerning blinding, v) risk of bias concerning missing 
outcomes 
The numbers in square brackets describe to what the coefficient refers. For example, in Figure 1a 
publication year: “B=2.74 (1.60, 3.88)  [10 years increase]” means a study that was conducted 10 years 
later had on average 2.74 (95% confidence interval 1.60 to 3.88) PANSS points higher placebo response. 
Or, as an example for a dichotomous explanatory variable: B = 5.96 (2.66, 9.26) [PANSS instead of 
BPRS] means that a study using the PANSS had on the average a 5.96 (95% confidence interval 2.66 to 
9.26) PANSS points higher placebo response. 
The explanatory variables are statistically significant if the 95% confidence interval does not include 1 
1 results without one outlier which was the only study restricted to elderly people with schizophrenia who 
had a mean age of 70 years, 20 years more than the next oldest study population,2  this meta-regression 
was also statistically significant when the only outlier study of a duration of 26 weeks was excluded 
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B=-1.11 (-4.57,2.36) 
[unclear risk] 
-2
0
-1
0
0
10
20
30
ch
an
ge
P
LA
tra
ns
0 1
Blinding
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B=-2.70 (-6.27,0.88) 
[unclear or high risk] 
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  Yes       Operationalised  diagnostic criteria              No   No                          Industry ponsorship                     Yes 
  Low                 Risk of bias randomisation          Unclear   Low                 Risk of bias allocation                   Unclear 
  Low                  Risk of bias : blinding     Unclear or high   Low/unclear     Risk of bias missing data                High 
q) r) 
s) t) 
u) v) 
w) -0.82(-4.52,2.89)  
[flexible dosing] 
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  Fixed                                 Dosing                           Flexible 
